Aurinia Pharmaceuticals (AUPH) to Release Quarterly Earnings on Monday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) is expected to be releasing its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Aurinia Pharmaceuticals to post earnings of $0.18 per share and revenue of $76.9790 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 11, 2026 at 8:30 AM ET.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $1.53 EPS for the quarter, beating the consensus estimate of $0.21 by $1.32. Aurinia Pharmaceuticals had a return on equity of 27.47% and a net margin of 101.46%.The firm had revenue of $77.11 million during the quarter, compared to analyst estimates of $74.70 million. On average, analysts expect Aurinia Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Aurinia Pharmaceuticals Stock Up 2.0%

Shares of AUPH traded up $0.30 during midday trading on Monday, hitting $15.65. 352,499 shares of the company’s stock traded hands, compared to its average volume of 1,062,523. Aurinia Pharmaceuticals has a 1 year low of $7.28 and a 1 year high of $16.88. The firm’s fifty day moving average is $15.05 and its 200-day moving average is $14.87. The company has a current ratio of 5.25, a quick ratio of 4.76 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $2.03 billion, a price-to-earnings ratio of 7.53 and a beta of 1.44.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday. Three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Aurinia Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $17.25.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang bought 516,439 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were purchased at an average cost of $13.99 per share, for a total transaction of $7,224,981.61. Following the transaction, the director directly owned 11,845,939 shares of the company’s stock, valued at approximately $165,724,686.61. The trade was a 4.56% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 12.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AUPH. Corient Private Wealth LLC raised its position in Aurinia Pharmaceuticals by 864.5% in the fourth quarter. Corient Private Wealth LLC now owns 275,472 shares of the biotechnology company’s stock valued at $4,394,000 after purchasing an additional 246,912 shares during the period. nVerses Capital LLC purchased a new stake in Aurinia Pharmaceuticals in the fourth quarter valued at approximately $406,000. Uniplan Investment Counsel Inc. raised its position in Aurinia Pharmaceuticals by 31.3% in the fourth quarter. Uniplan Investment Counsel Inc. now owns 120,202 shares of the biotechnology company’s stock valued at $1,917,000 after purchasing an additional 28,645 shares during the period. Voloridge Investment Management LLC raised its position in Aurinia Pharmaceuticals by 44.3% in the fourth quarter. Voloridge Investment Management LLC now owns 739,444 shares of the biotechnology company’s stock valued at $11,794,000 after purchasing an additional 226,875 shares during the period. Finally, Wellington Management Group LLP raised its position in Aurinia Pharmaceuticals by 4.7% in the fourth quarter. Wellington Management Group LLP now owns 53,721 shares of the biotechnology company’s stock valued at $857,000 after purchasing an additional 2,421 shares during the period. 36.83% of the stock is currently owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.